Alternative regimen for chemotherapy-intolerant lymphoma including practical aspects in Japan.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2025-04-06 DOI:10.1080/14737140.2025.2488317

Akihiro Ohmoto, Shigeo Fuji

{"title":"Alternative regimen for chemotherapy-intolerant lymphoma including practical aspects in Japan.","authors":"Akihiro Ohmoto, Shigeo Fuji","doi":"10.1080/14737140.2025.2488317","DOIUrl":null,"url":null,"abstract":"Introduction: With the increasing number of elderly patients with lymphoma and the emergence of novel agents, clinical investigations for patients considered intolerant to conventional cytotoxic chemotherapy are receiving more focus than before.Areas covered: This review aims to provide an overview of systemic treatment for patients with lymphoma who are intolerant to conventional chemotherapy, including practical aspects in Japan.Expert opinion: Traditional approaches include dose reduction (e.g. mini-CHOP) or non-anthracycline regimens (e.g. CVP or bendamustine-based regimens) to reduce the risk of cardiotoxicity. A recent trend is the combination of molecular-targeted agents, such as lenalidomide plus rituximab in B-cell lymphoma. However, maintaining durable responses remains a major challenge. In the future, clinical trials in elderly or frail patients are expected to investigate novel agents such as antibody-drug conjugates or bispecific T-cell engagers. In addition, comprehensive geriatric assessment for tailored therapeutic intervention or dose optimization strategies based on individual genomic data is expected in the context of prospective studies.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-11"},"PeriodicalIF":2.9000,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2488317","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: With the increasing number of elderly patients with lymphoma and the emergence of novel agents, clinical investigations for patients considered intolerant to conventional cytotoxic chemotherapy are receiving more focus than before.

Areas covered: This review aims to provide an overview of systemic treatment for patients with lymphoma who are intolerant to conventional chemotherapy, including practical aspects in Japan.

Expert opinion: Traditional approaches include dose reduction (e.g. mini-CHOP) or non-anthracycline regimens (e.g. CVP or bendamustine-based regimens) to reduce the risk of cardiotoxicity. A recent trend is the combination of molecular-targeted agents, such as lenalidomide plus rituximab in B-cell lymphoma. However, maintaining durable responses remains a major challenge. In the future, clinical trials in elderly or frail patients are expected to investigate novel agents such as antibody-drug conjugates or bispecific T-cell engagers. In addition, comprehensive geriatric assessment for tailored therapeutic intervention or dose optimization strategies based on individual genomic data is expected in the context of prospective studies.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.